Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

92.49 -1.53 (-1.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
52 53 Next >
FTX Contagion Spreads To Hong Kong Exchange, Microsoft Outlines New Harassment Policies, Netflix Subscribers Can Terminate Freeloading Account Access: Top Stories Wednesday, Nov. 16
Benzinga 
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Has This Hot Stock Run Out of Steam?
Shares of Gilead Sciences have been have been on a tear recently. 
Via The Motley Fool
Why Shares of Gilead Sciences Rose 27.20% in October
The company's growing oncology portfolio is driving increased revenues. 
Via The Motley Fool
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily... 
Via Benzinga
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way. 
Via The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 8.27% on an annualized basis producing an average annual return of 15.72%. Currently, Gilead Sciences has a market... 
Via Benzinga
Gilead Sciences Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in November
There's no need for agonizing decision-making with these great dividend stocks. 
Via The Motley Fool
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
From Gilead Sciences, Inc.
Via Business Wire
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
Via Benzinga
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
From Gilead Sciences, Inc.
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
From Gilead Sciences, Inc.
Via Business Wire
Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday
Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday. 
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
A Look Into Gilead Sciences's Debt
Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 26.52%. Before we understand the importance of debt, let's look at how much debt Gilead Sciences has. 
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
Healthcare & Biotech Stocks: A Big Opportunity In 2023
One of the areas that will come with opportunities for stock market investors in 2023 is the health care sector. This includes pharma, medical devices, biotech, and the likes. 
Via Talk Markets
These 2 Stock Winners Topped Apple's Big Gains Friday
Strong earnings helped lift the market. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Check Out What Whales Are Doing With GILD
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
Apple, Intel, And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.